NCT00651963已完成4 期
Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 80
- 主要终点
- Lipid profile
研究概览
简要总结
Gather additional efficacy and safety (pharmacovigilance) information in the usual daily care in patients with Dyslipidemia on ezetimibe under real conditions in Colombia associated with statins.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •> 18 years old
- •Lipid Metabolic Disorder as Per ATP III who have not reached the goals and who are on statins for at least 4 weeks Or those who require LDL reductions Over 50% to reach the ATP III goals or who need statins in accordance their risk score
排除标准
- •Pregnancy, Breast Feeding
- •Moderate/Sever Liver Disease: Child Score > Or = To 7
- •Fibrates Terminal Disease
- •Contraindications To Receive ezetimibe
- •Contraindications To Receive Statins
- •Mental Disability
- •Hypersensitivity To ezetimibe
- •On another Clinical Research Trial
结局指标
主要结局
Lipid profile
时间窗: Over 8 Weeks
次要结局
未报告次要终点
研究者
相似试验
已完成
3 期
Administration of Two Injections for Multiple Dupuytren's ContracturesDupuytren's ContractureNCT01407068Endo Pharmaceuticals60
Unknown
2 期
Dual Targeting of Vascular Endothelial Growth Factor-A Together With Angiopoietins in Chemotherapy-naïve Metastatic Colorectal CancerMetastatic Colorectal CancerNCT01249521Austin Health40
招募中
3 期
A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it WorksParoxysmal Nocturnal HemoglobinuriaNCT05744921Regeneron Pharmaceuticals202
已完成
1 期
Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic AdenocarcinomaMetastatic Pancreatic AdenocarcinomaNCT03214250Parker Institute for Cancer Immunotherapy129
No Longer Available
不适用
An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)FLT3-mutated Acute Myeloid LeukemiaNCT03114228Novartis Pharmaceuticals